J Appl Biomed 16:337-343, 2018 | DOI: 10.1016/j.jab.2018.03.003

Topic application of meloxicam-loaded polymeric nanocapsules as a technological alternative for treatment of the atopic dermatitis in mice

Douglas Mroginski Weber^a, Guilherme Teixeira Voss^a, Renata Leivas de Oliveira^a, Caren A.R. da Fonseca^a, Jaini Paltian^a, K.C. Rodrigues^a, Francine Rodrigues Ianiski^b, R.A. Vaucher^a, Cristiane Luchese^a,*, Ethel Antunes Wilhelm^a,*

^a Universidade Federal de Pelotas (UFPel), Centre for Chemical, Pharmaceutical and Food Sciences (CCQFA), Centre of Scientific Chemistry, Biochemistry and Bioprospecting Postgraduate Program (PPGBBio), Pelotas, Brazil

^b Centro Universitário Franciscano, CEP, Nanosciences Postgraduate Program, Santa Maria, Brazil

This study investigated the effect of the topical treatment with meloxicam-loaded nanocapsules (M-NC) on symptoms, inflammatory response and oxidative parameters in an atopic dermatitis (AD) model in BALB/c mice. 2,4-Dinitrochlorobenzene (DNCB) was applied to the dorsal skin on days 1-3 for sensitization. Mice were challenged with DNCB on the ear (on days 14-29) and dorsal skin (on days 14, 17, 20, 23, 26, and 29). Treatments with blank nanocapsules (B-NC), free meloxicam (M-F) or M-NC were applied to the backs of the mice from days 14 to 29. On the day 30, skin severity scores and scratching behaviour were determined. After that, ears and dorsal skin were removed for determination of inflammatory parameters (edema and myeloperoxidase (MPO) activity) and oxidative parameters (thiobarbituric acid reactive species (TBARS) and non-protein thiol (NPSH) levels), respectively. DNCB increased the severity of skin lesions, scratching behaviour, edema and MPO activity of ears and dorsal skin TBARS levels. M-NC reversed skin severity scores, scratching behaviour and inflammatory response induced by DNCB. B-NC and M-F did not have effect in this model. In summary, meloxicam carried by polymeric nanocapsules reversed inflammatory response and ameliorated symptoms in an AD model.

Keywords: Meloxicam; Nanoparticles; Nanotechnology; 2,4-Dinitrochlorobenzene; Non-steroidal anti-inflammatory drugs

Received: November 9, 2017; Revised: February 15, 2018; Accepted: March 13, 2018; Published: November 1, 2018  Show citation